Cargando…

Estimation of Overall Survival with Subsequent Treatment Effect by Applying Inverse Probability of Censoring Weighting in the LATITUDE Study

BACKGROUND: In the LATITUDE study (ClinicalTrials.gov, NCT01715285), compared with placebos, abiraterone acetate plus prednisone (AAP) with androgen deprivation therapy (ADT) provided significant overall survival (OS) benefit in high-risk metastatic castration-sensitive prostate cancer (mCSPC) patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Koroki, Yosuke, Taguri, Masataka, Matsubara, Nobuaki, Fizazi, Karim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783036/
https://www.ncbi.nlm.nih.gov/pubmed/35098170
http://dx.doi.org/10.1016/j.euros.2021.11.012
_version_ 1784638435564191744
author Koroki, Yosuke
Taguri, Masataka
Matsubara, Nobuaki
Fizazi, Karim
author_facet Koroki, Yosuke
Taguri, Masataka
Matsubara, Nobuaki
Fizazi, Karim
author_sort Koroki, Yosuke
collection PubMed
description BACKGROUND: In the LATITUDE study (ClinicalTrials.gov, NCT01715285), compared with placebos, abiraterone acetate plus prednisone (AAP) with androgen deprivation therapy (ADT) provided significant overall survival (OS) benefit in high-risk metastatic castration-sensitive prostate cancer (mCSPC) patients. It is controversial whether survival benefits would remain if all patients in the placebo group subsequently received life-extending therapies. OBJECTIVE: To estimate treatment effect in the case of all patients in the placebo group receiving life-extending subsequent therapies. DESIGN, SETTING, AND PARTICIPANTS: A post hoc analysis of LATITUDE final-analysis data was carried out (setting and participants have been reported previously). INTERVENTION: AAP or placebos plus ADT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We applied the inverse probability of censoring weighting (IPCW) method to represent the situation in which all patients in the placebo group would have received life-extending subsequent therapies. The OS hazard ratio (HR) of AAP versus placebos and associated 95% confidence interval (CI) were estimated using a Cox proportional hazards model. RESULTS AND LIMITATIONS: Of the 581 eligible patients in the placebo group, 237 (40.8%) did not receive life-extending subsequent therapies. From the unadjusted intention-to-treat analysis, the HR for OS for AAP versus placebos was 0.661 (95% CI 0.564–0.775). Using IPCW to adjust for patients in the placebo group without life-extending subsequent therapies, the HR was 0.732 (95% CI 0.604–0.887). A limitation is a lack of proof that the Cox proportional hazards model for the absence of life-extending subsequent therapy is correctly specified for the IPCW method. CONCLUSIONS: Treatment with AAP exerts OS benefit over placebos in high-risk mCSPC patients, regardless of whether life-extending subsequent therapy is given. PATIENT SUMMARY: In a previous study, high-risk metastatic castration-sensitive prostate cancer patients who received abiraterone acetate plus prednisone (AAP) with androgen deprivation therapy generally survived longer than those given placebos. The benefit of adding AAP continues regardless of whether life-extending subsequent therapy is given.
format Online
Article
Text
id pubmed-8783036
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-87830362022-01-28 Estimation of Overall Survival with Subsequent Treatment Effect by Applying Inverse Probability of Censoring Weighting in the LATITUDE Study Koroki, Yosuke Taguri, Masataka Matsubara, Nobuaki Fizazi, Karim Eur Urol Open Sci Prostate Cancer BACKGROUND: In the LATITUDE study (ClinicalTrials.gov, NCT01715285), compared with placebos, abiraterone acetate plus prednisone (AAP) with androgen deprivation therapy (ADT) provided significant overall survival (OS) benefit in high-risk metastatic castration-sensitive prostate cancer (mCSPC) patients. It is controversial whether survival benefits would remain if all patients in the placebo group subsequently received life-extending therapies. OBJECTIVE: To estimate treatment effect in the case of all patients in the placebo group receiving life-extending subsequent therapies. DESIGN, SETTING, AND PARTICIPANTS: A post hoc analysis of LATITUDE final-analysis data was carried out (setting and participants have been reported previously). INTERVENTION: AAP or placebos plus ADT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We applied the inverse probability of censoring weighting (IPCW) method to represent the situation in which all patients in the placebo group would have received life-extending subsequent therapies. The OS hazard ratio (HR) of AAP versus placebos and associated 95% confidence interval (CI) were estimated using a Cox proportional hazards model. RESULTS AND LIMITATIONS: Of the 581 eligible patients in the placebo group, 237 (40.8%) did not receive life-extending subsequent therapies. From the unadjusted intention-to-treat analysis, the HR for OS for AAP versus placebos was 0.661 (95% CI 0.564–0.775). Using IPCW to adjust for patients in the placebo group without life-extending subsequent therapies, the HR was 0.732 (95% CI 0.604–0.887). A limitation is a lack of proof that the Cox proportional hazards model for the absence of life-extending subsequent therapy is correctly specified for the IPCW method. CONCLUSIONS: Treatment with AAP exerts OS benefit over placebos in high-risk mCSPC patients, regardless of whether life-extending subsequent therapy is given. PATIENT SUMMARY: In a previous study, high-risk metastatic castration-sensitive prostate cancer patients who received abiraterone acetate plus prednisone (AAP) with androgen deprivation therapy generally survived longer than those given placebos. The benefit of adding AAP continues regardless of whether life-extending subsequent therapy is given. Elsevier 2022-01-06 /pmc/articles/PMC8783036/ /pubmed/35098170 http://dx.doi.org/10.1016/j.euros.2021.11.012 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Prostate Cancer
Koroki, Yosuke
Taguri, Masataka
Matsubara, Nobuaki
Fizazi, Karim
Estimation of Overall Survival with Subsequent Treatment Effect by Applying Inverse Probability of Censoring Weighting in the LATITUDE Study
title Estimation of Overall Survival with Subsequent Treatment Effect by Applying Inverse Probability of Censoring Weighting in the LATITUDE Study
title_full Estimation of Overall Survival with Subsequent Treatment Effect by Applying Inverse Probability of Censoring Weighting in the LATITUDE Study
title_fullStr Estimation of Overall Survival with Subsequent Treatment Effect by Applying Inverse Probability of Censoring Weighting in the LATITUDE Study
title_full_unstemmed Estimation of Overall Survival with Subsequent Treatment Effect by Applying Inverse Probability of Censoring Weighting in the LATITUDE Study
title_short Estimation of Overall Survival with Subsequent Treatment Effect by Applying Inverse Probability of Censoring Weighting in the LATITUDE Study
title_sort estimation of overall survival with subsequent treatment effect by applying inverse probability of censoring weighting in the latitude study
topic Prostate Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783036/
https://www.ncbi.nlm.nih.gov/pubmed/35098170
http://dx.doi.org/10.1016/j.euros.2021.11.012
work_keys_str_mv AT korokiyosuke estimationofoverallsurvivalwithsubsequenttreatmenteffectbyapplyinginverseprobabilityofcensoringweightinginthelatitudestudy
AT tagurimasataka estimationofoverallsurvivalwithsubsequenttreatmenteffectbyapplyinginverseprobabilityofcensoringweightinginthelatitudestudy
AT matsubaranobuaki estimationofoverallsurvivalwithsubsequenttreatmenteffectbyapplyinginverseprobabilityofcensoringweightinginthelatitudestudy
AT fizazikarim estimationofoverallsurvivalwithsubsequenttreatmenteffectbyapplyinginverseprobabilityofcensoringweightinginthelatitudestudy